Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Perflubutane→

Perflubutane Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
355-25-9
Molecular formula
C4F10
Molecular weight
238.03 g/mol
Drug class
Diagnostic ultrasound contrast agentperfluorobutane gas-filled microbubble
Mechanism of action
Perflubutane microbubbles circulate intravascularly and strongly scatter ultrasound waves, enhancing vascular and tissue perfusion signals. In the liver, the stabilised microbubbles are taken up by Kupffer cells, allowing vascular and postvascular (Kupffer) phase imaging.
Indications / reported uses
  • Contrast-enhanced ultrasound for evaluation of focal liver lesions in countries where Sonazoid is authorised.
  • In Japan, also used for selected breast-lesion ultrasound imaging under the relevant product authorisation. The diagnostic agent is the formulated perflubutane microbubble product, not the gas alone.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7446696/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC11499413/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Perflubutane Environmental Risk Assessment (ERA) (the Perflubutane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.